Vera Therapeutics, Inc. VERA
- TRUTAKNA — IgA Nephropathy Approved
- TRUTAKNA — Primary Membranous Nephropathy Phase 2
- TRUTAKNA — Focal Segmental Glomerulosclerosis Phase 2
- TRUTAKNA — Minimal Change Disease Phase 2
- VT-109 Preclinical
APRIL (4 companies · 9 programs)
Companies with an active program directed at APRIL.
Vor Biopharma Inc. VOR
- telitacicept — Generalized Myasthenia Gravis Phase 3
- telitacicept — Sjögren's Disease Phase 3
Climb Bio, Inc. CLYM
- CLYM116 — IgA Nephropathy Phase 1
Jade Biosciences, Inc. JBIO
- JADE101 — IgA Nephropathy Phase 2